Pancreatic EA2192

Study #EA2192

APOLLO: A Randomized Phase Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Back To Clinical Trials NCI Database Entry